6 January 2022
At the meeting of 8 December 2021 the RMA:
Determined Statements of Principles (SOPs) for:
| Condition | SOPs | |
|---|---|---|
| Hashimoto thyroiditis | 1/2022 | 2/2022 |
| hypothyroidism | 3/2022 | 4/2022 |
| hyperthyroidism and thyrotoxicosis | 5/2022 | 6/2022 |
| Graves disease | 7/2022 | 8/2022 |
| goitre | 9/2022 | 10/2022 |
| narcolepsy | 11/2022 | 12/2022 |
| aortic stenosis | 13/2022 | 14/2022 |
| colorectal adenoma | 15/2022 | 16/2022 |
| gingivitis | 17/2022 | 18/2022 |
| malignant neoplasm of the colon and rectum | 19/2022 | 20/2022 |
These SOPs revoke the SOPs previously determined for these conditions.
The above SOPs take effect from 31 January 2022.
Summary of Changes
Decided to Undertake Consultation regarding:
| Condition | Reasons for Decision | Date for Final Decision |
|---|---|---|
| morbid obesity | Intention to remove one or more factors | April 2022 |
| malignant neoplasm of the larynx | Intention to remove one or more factors | April 2022 |
Completed Investigations
The above determinations conclude the previously advertised investigations into:
New Investigation
Decided to advertise the following investigation:
- immune thrombocytopaenia (focussed review - SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) vaccines)
The above investigation notice appears in the Government Notices Gazette of 5 January 2022.